EORTC CLTF 2021 | Risk stratification of patients with PTCL using molecular profiling

Marta Rodriguez-Moreno, Instituto de Investigación Sanitaria, Fundación Jiménez Díaz University Hospital, Madrid, Spain, gives an overview of a study comparing the gene expression profiles of patients with the three peripheral T-cell lymphoma (PTCL) subtypes using a customized NanoString platform including 208 oncogenes and tumor suppressor genes. The analysis showed that a specific set of genes primarily expressed by follicular dendritic cells and mast cells was involved in processes associated with the diagnosis of PTCL subtypes. In addition, multivariate analysis identified gene sets associated with a change in survival for each of the three subtypes, thereby supporting the current division of PTCL into three prognostic categories. In particular, angioimmunoblastic T-cell lymphoma (AITL) was associated with expression of B-cell genes, PTCL not otherwise specified (PTCL-NOS) was associated with expression of proliferation genes, and PTCL with T follicular helper phenotype (PTCL-TFH) was associated with expression of cytotoxic genes. The B-cell gene set associated with a change in survival for patients with AITL was validated in an independent cohort. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.